Ibfla GEL Gel

Diclofenac Sodium 1% Topical
1.0%W/W
Arya Pharma Lab Pvt. Ltd.
Pack size 30gm
Dispensing mode
Source
Agent
Retail Price 85.00 NPR

Available as:

Indications

Ibfla GEL Gel is used for: Rheumatoid arthritis, Osteoarthritis, Joint and muscular pains

Adult Dose

Topical/Cutaneous Osteoarthritis Adult: Apply 2 g (upper extremities)/4 g (lower extremities) q6hr Not to exceed 8 g/day to any single joint of (upper) extremities; 16 g/day to any single joint of (lower extremities) Local symptomatic relief of pain and inflammation Adult: As diclofenac Na (1% gel): Apply onto affected area 3 or 4 times daily.

Child Dose

Safety and efficacy not established

Renal Dose

Administration

Apply to clean, dry skin Avoid showering/bathing until gel/solution is dry for at least 30 min Wash hands after use Avoid clothing on knees until gel/solution is dry

Contra Indications

Contraindicated to the patients hypersensitive to any ingredient of the products. Peptic ulcer, hypersensitivity to Diclofenac like other non-steroid anti-inflammatory agents, Diclofenac is also contra-indicated in asthmatic patient in whom attack with asthma, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or by other drugs with prostaglandin synthetase inhibitor. Gel should not be used under occlusive airtight dressings.

Precautions

In rare instances where peptic ulceration or gastro-intestinal bleeding occurs in patients under treatment with Diclofenac. In patients with advanced age should be kept under close observation.Gel should not be allowed to come in contact with the eyes or mucus membranes, after application the hands should be washed properly and not to be taken by mouth. Lactation: Excretion in milk unknown/not recommended

Pregnancy-Lactation

Pregnancy Category: 1st and 2nd trimesters - C; category D during 3rd trimester because of risk for premature closure of the ductus arteriosus

Interactions

May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.

Adverse Effects

Side effects of Diclofenac Sodium 1% Topical : >10% Dry skin (25-27%),Rash (20-35%),Contact dermatitis (19-33%),Pain (15-26%),Paresthesia (<20%),Pruritus (52%),Exfoliation (6-24%) 1-10% Hypertension,Chest pain,Skin ulcer,Diarrhea,Dyspepsia,Alepesia,Photosensitivity,Edema,Conjunctivitis,Hematuria,Asthma,Pneumonia

Mechanism of Action

Diclofenac, a phenylacetic acid derivative is a prototypical NSAID. It has potent anti-inflammatory, analgesic and antipyretic actions. Inhibits cyclooxygenase (COX)-1 and COX-2, thereby inhibiting prostaglandin synthesis. May also inhibit neutrophil aggregation/activation, inhibit chemotaxis, decrease proinflammatory cytokine level, and alter lymphocyte activity.

Note

Ibfla GEL 1.0%W/W Gel manufactured by Arya Pharma Lab Pvt. Ltd.. Its generic name is Diclofenac Sodium 1% Topical. Ibfla GEL is availble in Nepal. Farmaco Nepal drug index information on Ibfla GEL Gel is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Diclofenac Sodium 1% Topical :